GX Acquisition in an SEC filing shared a slide deck it will use for investor presentations on its pending merger with Celularity, a clinical-stage biotechnology company.
Deal terms call for Celularity to receive $372 million, consisting of $292 million held in trust by GX as well as an $80 million PIPE.
Separately, GX is asking shareholders to grant a deadline extension until July 31 to close the deal. A shareholder vote on that proposal is set for May 14. Read more.
